Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study—East Shizuoka Tirzepatide (ESTATE) study
Abstract
The glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide is available clinically. Although real-world studies of tirzepatide in Japanese people with type 2 diabetes (T2D) have been reported, data regarding low-dose tirzepatide and patient-reported outcomes in routine clinical practice remain limited. In this multicenter retrospective observational study, we evaluated changes in glycemic control, body mass index (BMI), metabolic parameters, patient-reported outcomes, and adverse events after initiation of low-dose tirzepatide in Japanese people with T2D. Eighty-eight subjects with T2D treated with an average dose of tirzepatide of 4.5 ± 1.0 mg/week for 24 weeks were retrospectively analyzed. The primary outcomes were changes in glycated hemoglobin (HbA1c) and BMI from baseline to 24 weeks. HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, –1.5%; BMI, –1.5 kg/m2; both p < 0.001). Additionally, serum albumin was increased, and alanine transaminase and low-density lipoprotein cholesterol were decreased significantly. In multivariable regression analysis, higher baseline HbA1c was associated with greater HbA1c reduction. In exploratory cross-sectional analyses, post-treatment Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores were associated with higher baseline HbA1c, and Kanden Institute Stigma Scale (KISS) scores were associated with higher baseline BMI. Major adverse events linked with tirzepatide were gastrointestinal symptoms. In this multicenter retrospective single-arm observational study, HbA1c and BMI decreased over 24 weeks after low-dose tirzepatide initiation in Japanese people with T2D. These findings suggest that low-dose tirzepatide may be a useful treatment option in selected patients in routine clinical practice, although causal inference is limited by the observational design and lack of a control group.
Related
- Body Composition Changes With Standard Versus Low-Dose Tirzepatide Titration in Women With Lipedema: A Retrospective Observational Study.
- Effectiveness and Patient Compliance of a Needle-Free Injection System in Controlled Ovarian Stimulation in IVF Cycles: A Real-World, Investigator-Initiated, Retrospective, Multicenter, Observational Study
- SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity
- 12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.
- Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.
BibTeX
@article{iwamoto2026realworld,
title = {{Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study—East Shizuoka Tirzepatide (ESTATE) study}},
author = {Tatsuya Iwamoto and Nozomu Yamasaki and Shuko Nojiri and Wataru Urasaki and Katsumi Aso and Katsutoshi Komatsu and Naoko Enosawa and Marie Kanzaki and Daisuke Takarabe and Jo Nagakura and Ken Sato and Naoaki Ito and Hirotaka Watada and Takashi Nomiyama and Collaborators of East Shizuoka Tirzepatide study},
journal = {Endocrine Journal},
year = {2026},
month = sep,
doi = {10.1507/endocrj.ej26-0274},
url = {https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0274/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study—East Shizuoka Tirzepatide (ESTATE) study
AU - Tatsuya Iwamoto
AU - Nozomu Yamasaki
AU - Shuko Nojiri
AU - Wataru Urasaki
AU - Katsumi Aso
AU - Katsutoshi Komatsu
AU - Naoko Enosawa
AU - Marie Kanzaki
AU - Daisuke Takarabe
AU - Jo Nagakura
AU - Ken Sato
AU - Naoaki Ito
AU - Hirotaka Watada
AU - Takashi Nomiyama
AU - Collaborators of East Shizuoka Tirzepatide study
PY - 2026
DA - 2026/09/29
JO - Endocrine Journal
DO - 10.1507/endocrj.ej26-0274
UR - https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0274/_article
AB - The glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide is available clinically. Although real-world studies of tirzepatide in Japanese people with type 2 diabetes (T2D) have been reported, data regarding low-dose tirzepatide and patient-reported outcomes in routine clinical practice remain limited. In this multicenter retrospective observational study, we evaluated changes in glycemic control, body mass index (BMI), metabolic parameters, patient-reported outcomes, and adverse events after initiation of low-dose tirzepatide in Japanese people with T2D. Eighty-eight subjects with T2D treated with an average dose of tirzepatide of 4.5 ± 1.0 mg/week for 24 weeks were retrospectively analyzed. The primary outcomes were changes in glycated hemoglobin (HbA1c) and BMI from baseline to 24 weeks. HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, –1.5%; BMI, –1.5 kg/m2; both p < 0.001). Additionally, serum albumin was increased, and alanine transaminase and low-density lipoprotein cholesterol were decreased significantly. In multivariable regression analysis, higher baseline HbA1c was associated with greater HbA1c reduction. In exploratory cross-sectional analyses, post-treatment Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores were associated with higher baseline HbA1c, and Kanden Institute Stigma Scale (KISS) scores were associated with higher baseline BMI. Major adverse events linked with tirzepatide were gastrointestinal symptoms. In this multicenter retrospective single-arm observational study, HbA1c and BMI decreased over 24 weeks after low-dose tirzepatide initiation in Japanese people with T2D. These findings suggest that low-dose tirzepatide may be a useful treatment option in selected patients in routine clinical practice, although causal inference is limited by the observational design and lack of a control group.
SN - 1348-4540
SN - 0918-8959
ER -